Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia

Olayinka Okeleji(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Miriam B. Garcia(The University of Texas MD Anderson Cancer Center), Michael Roth(The University of Texas MD Anderson Cancer Center), Branko Cuglievan(The University of Texas MD Anderson Cancer Center), Jeremy Connors(The University of Texas MD Anderson Cancer Center), David McCall(The University of Texas MD Anderson Cancer Center), Amber Gibson(The University of Texas MD Anderson Cancer Center), César Núnêz(The University of Texas MD Anderson Cancer Center), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center)
Blood Advances
February 24, 2025
10.1182/bloodadvances.2024015527
Cited by 4

Related Papers

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
|Scientific Reports|2016|263
Navigating financial toxicity in patients with cancer: A multidisciplinary management approach
|CA A Cancer Journal for Clinicians|2022|251
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237
Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation
|Blood|2012|167
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
|Cancer|2013|157